Table 1.
Diagnosis and treatment contents
| CC | CC + HDC | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Numbers of subjects | (+IR) | Alkylators in the multi-agent HDC | (+IR) | |||||||||
| Diagnosis | Total | Subtotal | CRI/CSI/FI | Subtotal | Bus | Cyc | Mel | Tio | Ran | Ifo | TBI | CRI/CSI/FI |
| ALL | 26 | 19 | 8 | 7 | 3 | 6 | 1 | 0 | 1 | 0 | 5 | 4 |
| AML | 6 | 2 | 0 | 4 | 4 | 1 | 3 | 0 | 0 | 0 | 0 | 0 |
| MBL | 4 | 1 | 1 | 3 | 1 | 2 | 1 | 2 | 1 | 0 | 0 | 3 |
| PNET | 2 | 0 | 0 | 2 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| NBL | 2 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| HBL | 2 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| SB | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| ACC | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ML | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WT | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
| Total | 46 | 26 | 10 | 20* | 11 | 11 | 9 | 6 | 2 | 1 | 6† | 10‡ |
Seven subjects without IR.
Three subjects with TBI (12 Gy) only.
Seven subjects with CRI/CSI/FI only.
†,‡Three subjects with TBI and CRI/CSI/FI.
Single dose values of alkylators as follows: busulfan (Bus) 448–576 mg/m2, cyclophosphamide (Cyc) 1200–4500 mg/m2, melphalan (Mel) 180–540 mg/m2, thiotepa (Tio) 600–900 mg/m2, ranimustine (Ran) 250–450 mg/m2, ifosfamide (Ifo) 480 g/m2.
ACC, adrenal cortical carcinoma; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CC, conventional chemotherapy; CRI, cranial irradiation; CSI, craniospinal irradiation; FI, focal irradiation; HBL, hepatoblastoma; HDC, high-dose chemotherapy; IR, irradiation; MBL, medullo blastoma; NBL, neuroblastoma; NHL, non-Hodgkin's lymphoma; PNET, primitive neuroectodermal tumour; SB, undifferentiated sarcoma of bone; WT, Wilm's tumour.